Stockscreener 앱 받기
252.16
0.10%
0.25
시간 외 거래:
254.74
2.58
+1.02%
전일 마감가:
$251.91
열려 있는:
$251.13
하루 거래량:
519.42K
Relative Volume:
0.72
시가총액:
$12.98B
수익:
$708.24M
순이익/손실:
$-188.30M
주가수익비율:
-67.44
EPS:
-3.7392
순현금흐름:
$-70.99M
1주 성능:
+2.36%
1개월 성능:
+10.73%
6개월 성능:
+70.38%
1년 성능:
+148.19%
1일 변동 폭
$248.64
$254.84
1주일 범위
$247.69
$257.93
52주 변동 폭
$96.09
$257.93
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
252.16 | 13.04B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | 개시 | B. Riley Securities | Buy |
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 개시 | Oppenheimer | Outperform |
| 2025-04-07 | 개시 | Jefferies | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-31 | 재확인 | Mizuho | Outperform |
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Axsome presents data on narcolepsy treatments at sleep conference By Investing.com - Investing.com South Africa
Axsome presents data on narcolepsy treatments at sleep conference - Investing.com
Axsome Therapeutics Presents New Data on AXS-12 and Solriamfetol at SLEEP 2026 Conference - Quiver Quantitative
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026 - GlobeNewswire
Axsome Therapeutics (AXSM) Stock Analysis: 57% Revenue Growth Propels Exciting Prospects - DirectorsTalk Interviews
Landscape Capital Management L.L.C. Sells 3,983 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
First Turn Management LLC Has $37.79 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Nicholas Investment Partners LP Purchases 42,907 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Eventide Asset Management LLC Sells 175,172 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
The Technical Signals Behind (AXSM) That Institutions Follow - Stock Traders Daily
Rhenman & Partners Asset Management AB Reduces Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
Axsome therapeutics director Roger Jeffs sells $141,655 in shares By Investing.com - Investing.com India
Axsome therapeutics director Roger Jeffs sells $141,655 in shares - Investing.com UK
Axsome Therapeutics, Inc. (AXSM) Latest Stock News & Headlines - Yahoo Finance
Agitation in Alzheimer's Disease Market to Register Immense Growth at a CAGR of 14.9% During the Forecast Period (2026-2036) | DelveInsight - PR Newswire
Axsome Therapeutics, Inc. $AXSM Shares Sold by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. - MarketBeat
Jefferies raises Axsome stock price target to $380 on sales outlook By Investing.com - Investing.com South Africa
Jefferies raises Axsome stock price target to $380 on sales outlook - Investing.com Canada
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 12-Month HighShould You Buy? - MarketBeat
Clearbridge Investments LLC Sells 11,341 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics (AXSM) 10K Form and Latest SEC Filings 2026 - MarketBeat
Axsome Therapeutics readies Auvelity Alzheimer's agitation launch, expands CNS pipeline - MSN
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) Director Sells 643 Shares of Stock - MarketBeat
Axsome Therapeutics director Susan Mahony sells $145,017 in shares By Investing.com - Investing.com India
Axsome Therapeutics director Susan Mahony sells $145,017 in shares - Investing.com UK
Axsome therapeutics director Mark Coleman sells $160,107 in stock By Investing.com - Investing.com India
Axsome therapeutics director Mark Coleman sells $160,107 in stock - Investing.com
Axsome adopts new executive severance and control plan - The Globe and Mail
Axsome Therapeutics(AXSM.US) 10% Shareholder Sells US$11.97 Million in Common Stock - Moomoo
Axsome Therapeutics stock hits all-time high at 242.5 USD By Investing.com - Investing.com Canada
Axiom Investors LLC DE Purchases 14,137 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics CEO Herriot Tabuteau sells $11.97m in stock - Investing.com India
Axsome Therapeutics CEO Herriot Tabuteau sells $11.97m in stock By Investing.com - Investing.com Australia
[144] Axsome Therapeutics, Inc. SEC Filing - Stock Titan
Axsome Therapeutics (AXSM) sets new executive severance and change in control terms - Stock Titan
Axsome Therapeutics (AXSM) investors approve directors, auditor and executive pay - Stock Titan
Axsome Therapeutics (NASDAQ: AXSM) grants director 1,721 restricted stock units - Stock Titan
Axsome Therapeutics (AXSM) director awarded 1,721 restricted stock units - Stock Titan
Axsome (NASDAQ: AXSM) CEO sells 49,670 shares after expiring option exercise - Stock Titan
Axsome (AXSM) CFO sells 33K shares after exercising long-held options - Stock Titan
Axsome Therapeutics (AXSM) director awarded 1,721 RSUs vesting in one year - Stock Titan
Axsome (AXSM) director receives 1,721 restricted stock units as compensation - Stock Titan
Axsome Therapeutics, Inc.Common Stock (NQ: AXSM - FinancialContent
Axsome Therapeutics stock hits all-time high at 242.5 USD - Investing.com
AXSM: AUVELITY's new approval and sales force expansion drive strong growth in CNS markets - TradingView
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: A Biotech Dynamo with a 16% Upside Potential - DirectorsTalk Interviews
Axsome marks ending of all patent disputes related to Sunosi - MSN
Norges Bank Makes New $90.49 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline - inkl
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Axsome Therapeutics Inc 주식 (AXSM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| JEFFS ROGER | Director |
Jun 10 '26 |
Sale |
246.18 |
286 |
70,407 |
58,653 |
2.60%
0.94%
자본화:
|
볼륨(24시간):